{"id":236138,"date":"2026-09-09T10:15:03","date_gmt":"2026-09-09T04:45:03","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=236138"},"modified":"2026-09-09T10:15:03","modified_gmt":"2026-09-09T04:45:03","slug":"ajanta-pharma-q2-results-fy27-preview-date-expectations","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/","title":{"rendered":"Ajanta Pharma Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Ajanta Pharma share price Rs 3,552.70 on 9 September 2026, down 0.74%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 334.22 crore. Q2 FY26 base a profit of Rs 260.19 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Ajanta Pharma Q2 results date for FY27 is not confirmed, and Ajanta Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 1,413.07 crore in revenue and a profit of Rs 260.19 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.<\/p>\n<\/p><\/div>\n<p>The Ajanta Pharma Q2 results FY27 announcement is the next scheduled earnings event for <a href=\"https:\/\/univest.in\/stocks\/ajantpharm\/ajanta-pharma-ltd-share-price-today\">Ajanta Pharma Ltd.<\/a>, a branded generics pharmaceutical company selling in India, Asia and Africa alongside a United States generics business, with strengths in cardiology, dermatology and ophthalmology. The stock traded at Rs 3,552.70 on the NSE on 9 September 2026, down 0.74% from the previous close of Rs 3,579.30, about 6.4% below its 52-week high of Rs 3,796.00 and 52.5% above its 52-week low of Rs 2,329.90.<\/p>\n<p>What makes the Ajanta Pharma Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 1,413.07 crore of revenue and a profit of Rs 260.19 crore, while the most recent quarter on record, Q1 FY27, produced Rs 1,696.86 crore and a profit of Rs 334.22 crore. Everything below is built from those reported figures rather than from any forecast.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=ajantpharm_q2_fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#When_Is_the_Ajanta_Pharma_Q2_Results_FY27_Date\" title=\"When Is the Ajanta Pharma Q2 Results FY27 Date?\">When Is the Ajanta Pharma Q2 Results FY27 Date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#Ajanta_Pharma_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\" title=\"Ajanta Pharma Q2 Results Expectations: What the Market Is Actually Tracking\">Ajanta Pharma Q2 Results Expectations: What the Market Is Actually Tracking<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#Ajanta_Pharma_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\" title=\"Ajanta Pharma Q2 Results Preview: The Q1 FY27 Actuals It Builds On\">Ajanta Pharma Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#Q2_FY26_Base_The_Comparison_Ajanta_Pharma_Q2_Results_FY27_Must_Beat\" title=\"Q2 FY26 Base: The Comparison Ajanta Pharma Q2 Results FY27 Must Beat\">Q2 FY26 Base: The Comparison Ajanta Pharma Q2 Results FY27 Must Beat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#Ajanta_Pharma_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\" title=\"Ajanta Pharma Quarterly Results Trend Over the Last Four Quarters\">Ajanta Pharma Quarterly Results Trend Over the Last Four Quarters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#Key_Factors_That_Could_Shape_Ajanta_Pharma_Q2_Results_FY27\" title=\"Key Factors That Could Shape Ajanta Pharma Q2 Results FY27\">Key Factors That Could Shape Ajanta Pharma Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#Branded_Markets_Versus_United_States_Generics\" title=\"Branded Markets Versus United States Generics\">Branded Markets Versus United States Generics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#New_Launches_and_Therapy_Mix\" title=\"New Launches and Therapy Mix\">New Launches and Therapy Mix<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#Strong_Returns_at_a_Full_Valuation\" title=\"Strong Returns at a Full Valuation\">Strong Returns at a Full Valuation<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#Ajanta_Pharma_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\" title=\"Ajanta Pharma Q2 Results FY27: Share Price and Valuation Going Into the Print\">Ajanta Pharma Q2 Results FY27: Share Price and Valuation Going Into the Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#What_Investors_Should_Watch_When_Ajanta_Pharma_Q2_Results_Are_Announced\" title=\"What Investors Should Watch When Ajanta Pharma Q2 Results Are Announced\">What Investors Should Watch When Ajanta Pharma Q2 Results Are Announced<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#Conclusion_on_Ajanta_Pharma_Q2_Results_FY27\" title=\"Conclusion on Ajanta Pharma Q2 Results FY27\">Conclusion on Ajanta Pharma Q2 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#FAQs_on_Ajanta_Pharma_Q2_Results_FY27\" title=\"FAQs on Ajanta Pharma Q2 Results FY27\">FAQs on Ajanta Pharma Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#What_is_the_Ajanta_Pharma_Q2_results_date_for_FY27\" title=\"What is the Ajanta Pharma Q2 results date for FY27?\">What is the Ajanta Pharma Q2 results date for FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#What_quarter_do_the_Ajanta_Pharma_Q2_results_2026_cover\" title=\"What quarter do the Ajanta Pharma Q2 results 2026 cover?\">What quarter do the Ajanta Pharma Q2 results 2026 cover?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#What_were_the_Ajanta_Pharma_Q1_FY27_results\" title=\"What were the Ajanta Pharma Q1 FY27 results?\">What were the Ajanta Pharma Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#What_were_Ajanta_Pharma_Q2_FY26_results_in_the_September_2025_quarter\" title=\"What were Ajanta Pharma Q2 FY26 results in the September 2025 quarter?\">What were Ajanta Pharma Q2 FY26 results in the September 2025 quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#What_are_the_main_Ajanta_Pharma_Q2_results_expectations_this_quarter\" title=\"What are the main Ajanta Pharma Q2 results expectations this quarter?\">What are the main Ajanta Pharma Q2 results expectations this quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#What_is_Ajanta_Pharma_share_price_today_ahead_of_the_Q2_earnings\" title=\"What is Ajanta Pharma share price today ahead of the Q2 earnings?\">What is Ajanta Pharma share price today ahead of the Q2 earnings?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q2-results-fy27-preview-date-expectations\/#Is_Ajanta_Pharma_a_good_stock_to_buy_before_the_Q2_results\" title=\"Is Ajanta Pharma a good stock to buy before the Q2 results?\">Is Ajanta Pharma a good stock to buy before the Q2 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"When_Is_the_Ajanta_Pharma_Q2_Results_FY27_Date\"><\/span><strong>When Is the Ajanta Pharma Q2 Results FY27 Date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Ajanta Pharma Q2 results date for FY27 is not confirmed. As of 9 September 2026, Ajanta Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.<\/p>\n<p>What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Ajanta Pharma Q2 results date becomes public through that filing rather than through any advance announcement.<\/p>\n<p>The Ajanta Pharma Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Ajanta Pharma.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ajanta_Pharma_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\"><\/span><strong>Ajanta Pharma Q2 Results Expectations: What the Market Is Actually Tracking<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No verified analyst estimate for the Ajanta Pharma Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Ajanta Pharma. The Ajanta Pharma Q2 results watchlist below is built from what the company has actually reported and disclosed.<\/p>\n<p>The first is the June quarter&#8217;s step up. Revenue reached Rs 1,696.86 crore in Q1 FY27, well above the Rs 1,483.07 crore of the preceding quarter, and profit rose to Rs 334.22 crore with operating margin improving to 30.41%.<\/p>\n<p>The second is the branded generics engine. India, Asia and Africa branded sales carry better economics than the American generics business, so the geographic mix decides how much of a revenue increase reaches profit.<\/p>\n<p>The third is the September 2025 base of Rs 1,413.07 crore in revenue and Rs 260.19 crore in profit at a 28.60% margin. Growth against that base looks achievable on the current run rate, which shifts attention to whether margin holds above 30%.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Ajanta Pharma Ltd. Live Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ajanta_Pharma_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\"><\/span><strong>Ajanta Pharma Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ajanta Pharma Ltd. reported revenue of Rs 1,696.86 crore in Q1 FY27, up 27.68% from Rs 1,328.98 crore in Q1 FY26, and a profit of Rs 334.22 crore at the net level, up 30.89% from Rs 255.34 crore in Q1 FY26. These are reported actuals, not estimates.<\/p>\n<p>Sequentially, revenue was up 14.42% over the March 2026 quarter figure of Rs 1,483.07 crore, and net profit was up 25.32% from Rs 266.70 crore in Q4 FY26. Operating margin stood at 30.41% in Q1 FY27 against 28.60% in the September 2025 quarter, which is the comparison the Ajanta Pharma Q2 results print will be read against.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY26_Base_The_Comparison_Ajanta_Pharma_Q2_Results_FY27_Must_Beat\"><\/span><strong>Q2 FY26 Base: The Comparison Ajanta Pharma Q2 Results FY27 Must Beat<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ajanta Pharma Ltd. reported revenue of Rs 1,413.07 crore and a profit of Rs 260.19 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Ajanta Pharma Q2 results preview.<\/p>\n<p>Net profit in that base quarter was below the Rs 334.22 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 1,413.07 crore sits below the Rs 1,696.86 crore of the June 2026 quarter, which frames how much sequential movement the Ajanta Pharma Q2 results print needs to show growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ajanta_Pharma_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\"><\/span><strong>Ajanta Pharma Quarterly Results Trend Over the Last Four Quarters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Q2 FY26 (Sep 2025)<\/td>\n<td>1,413.07<\/td>\n<td>260.19<\/td>\n<\/tr>\n<tr>\n<td>Q3 FY26 (Dec 2025)<\/td>\n<td>1,399.81<\/td>\n<td>273.77<\/td>\n<\/tr>\n<tr>\n<td>Q4 FY26 (Mar 2026)<\/td>\n<td>1,483.07<\/td>\n<td>266.70<\/td>\n<\/tr>\n<tr>\n<td>Q1 FY27 (Jun 2026)<\/td>\n<td>1,696.86<\/td>\n<td>334.22<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company&#8217;s exchange filings, and they are the only basis this Ajanta Pharma Q2 results preview uses.<\/p>\n<p>Revenue across those four quarters ranged from Rs 1,399.81 crore to Rs 1,696.86 crore, and net profit from Rs 260.19 crore to Rs 334.22 crore. That spread is the honest context for the Ajanta Pharma Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Factors_That_Could_Shape_Ajanta_Pharma_Q2_Results_FY27\"><\/span><strong>Key Factors That Could Shape Ajanta Pharma Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Ajanta Pharma Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Ajanta Pharma has already reported.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Branded_Markets_Versus_United_States_Generics\"><\/span><strong>Branded Markets Versus United States Generics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Africa and Asia branded sales are prescription-led and less exposed to price erosion, while the American business faces continuous generic price pressure. The balance between them is the main margin variable.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"New_Launches_and_Therapy_Mix\"><\/span><strong>New Launches and Therapy Mix<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Cardiology, dermatology and ophthalmology each behave differently through the year. New product introductions in the branded markets are what sustain growth above the underlying market rate.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Strong_Returns_at_a_Full_Valuation\"><\/span><strong>Strong Returns at a Full Valuation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ajanta Pharma generates a return on equity of 23.33% with a debt-to-equity ratio of 0.06, and trades at a price-to-earnings ratio of 39.46 against a sector average of 37.99 and 9.89 times book value.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ajanta_Pharma_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\"><\/span><strong>Ajanta Pharma Q2 Results FY27: Share Price and Valuation Going Into the Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ajanta Pharma share price today is Rs 3,552.70 on the NSE, down Rs 26.60 or 0.74% from the previous close of Rs 3,579.30 on 9 September 2026, ahead of the Ajanta Pharma Q2 results announcement.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value (8 September 2026)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NSE Symbol<\/td>\n<td>AJANTPHARM<\/td>\n<\/tr>\n<tr>\n<td>Current Market Price<\/td>\n<td>Rs 3,552.70<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 3,796.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 2,329.90<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>Rs 44,778 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio<\/td>\n<td>39.46<\/td>\n<\/tr>\n<tr>\n<td>Sector PE<\/td>\n<td>37.99<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>9.89<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 90.82<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>Rs 362.28<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.06<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>23.33%<\/td>\n<\/tr>\n<tr>\n<td>50-Day Moving Average<\/td>\n<td>Rs 3,489.93<\/td>\n<\/tr>\n<tr>\n<td>200-Day Moving Average<\/td>\n<td>Rs 3,029.30<\/td>\n<\/tr>\n<tr>\n<td>RSI (14)<\/td>\n<td>40.05<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock trades above both its 50-day average of Rs 3,489.93 and its 200-day average of Rs 3,029.30, with a 14-day RSI of 40.05. None of this is a view on where the shares go once the Ajanta Pharma Q2 results are announced, and no price target is offered here.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Ajanta Pharma Ltd. live price and quarterly earnings updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch_When_Ajanta_Pharma_Q2_Results_Are_Announced\"><\/span><strong>What Investors Should Watch When Ajanta Pharma Q2 Results Are Announced<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four lines carry most of the information in a company of this size, and reading them in order keeps the Ajanta Pharma Q2 results print in proportion.<\/p>\n<ol>\n<li>Revenue against the Rs 1,413.07 crore reported in the September 2025 base quarter<\/li>\n<li>Net profit against a profit of Rs 260.19 crore in that same quarter<\/li>\n<li>Operating margin against 30.41% in Q1 FY27<\/li>\n<li>Any exceptional item, provision or one-off gain disclosed alongside the numbers<\/li>\n<\/ol>\n<p>A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Ajanta Pharma Q2 results announcement should be read together with the notes to the results rather than the headline alone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Ajanta_Pharma_Q2_Results_FY27\"><\/span><strong>Conclusion on Ajanta Pharma Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Ajanta Pharma Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Ajanta Pharma Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.<\/p>\n<p>On that basis the Ajanta Pharma Q2 results FY27 print faces a base of Rs 1,413.07 crore in revenue and a profit of Rs 260.19 crore, with the most recent quarter having delivered Rs 1,696.86 crore and a profit of Rs 334.22 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Ajanta Pharma, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Ajanta_Pharma_Q2_Results_FY27\"><\/span><strong>FAQs on Ajanta Pharma Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Ajanta_Pharma_Q2_results_date_for_FY27\"><\/span><strong>What is the Ajanta Pharma Q2 results date for FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Ajanta Pharma Q2 results date for FY27 is not confirmed. Ajanta Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_quarter_do_the_Ajanta_Pharma_Q2_results_2026_cover\"><\/span><strong>What quarter do the Ajanta Pharma Q2 results 2026 cover?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Ajanta Pharma Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Ajanta Pharma Ltd. reports revenue, operating profit and net profit for that period, and the Ajanta Pharma Q2 results filing also carries the notes to the accounts.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Ajanta_Pharma_Q1_FY27_results\"><\/span><strong>What were the Ajanta Pharma Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Ajanta Pharma Ltd. reported revenue of Rs 1,696.86 crore in Q1 FY27 and a profit of Rs 334.22 crore at the net level. Revenue was up 27.68% versus Q1 FY26 and net profit was up 30.89% from Rs 255.34 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Ajanta_Pharma_Q2_FY26_results_in_the_September_2025_quarter\"><\/span><strong>What were Ajanta Pharma Q2 FY26 results in the September 2025 quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Ajanta Pharma Ltd. reported revenue of Rs 1,413.07 crore and a profit of Rs 260.19 crore in Q2 FY26. Operating margin was 28.60%. Those figures form the base for the Ajanta Pharma Q2 results FY27 comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_Ajanta_Pharma_Q2_results_expectations_this_quarter\"><\/span><strong>What are the main Ajanta Pharma Q2 results expectations this quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No verified analyst estimate is publicly available. The Ajanta Pharma Q2 results expectations centre on revenue against the Rs 1,413.07 crore base, net profit against a profit of Rs 260.19 crore, operating margin against 30.41% in Q1 FY27, and any exceptional item disclosed with the numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Ajanta_Pharma_share_price_today_ahead_of_the_Q2_earnings\"><\/span><strong>What is Ajanta Pharma share price today ahead of the Q2 earnings?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Ajanta Pharma share price is Rs 3,552.70 on the NSE as of 9 September 2026, down 0.74% from Rs 3,579.30. The stock is about 6.4% below its 52-week high of Rs 3,796.00 and 52.5% above its 52-week low of Rs 2,329.90, at a market capitalisation of Rs 44,778 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Ajanta_Pharma_a_good_stock_to_buy_before_the_Q2_results\"><\/span><strong>Is Ajanta Pharma a good stock to buy before the Q2 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not offer a buy, sell or hold recommendation on Ajanta Pharma Ltd.. The stock trades at a price-to-book ratio of 9.89 with a return on equity of 23.33%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Ajanta Pharma Q2 results date for FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Ajanta Pharma Q2 results date for FY27 is not confirmed. Ajanta Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.\"}},{\"@type\":\"Question\",\"name\":\"What quarter do the Ajanta Pharma Q2 results 2026 cover?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Ajanta Pharma Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Ajanta Pharma Ltd. reports revenue, operating profit and net profit for that period, and the Ajanta Pharma Q2 results filing also carries the notes to the accounts.\"}},{\"@type\":\"Question\",\"name\":\"What were the Ajanta Pharma Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Ajanta Pharma Ltd. reported revenue of Rs 1,696.86 crore in Q1 FY27 and a profit of Rs 334.22 crore at the net level. Revenue was up 27.68% versus Q1 FY26 and net profit was up 30.89% from Rs 255.34 crore in Q1 FY26.\"}},{\"@type\":\"Question\",\"name\":\"What were Ajanta Pharma Q2 FY26 results in the September 2025 quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Ajanta Pharma Ltd. reported revenue of Rs 1,413.07 crore and a profit of Rs 260.19 crore in Q2 FY26. Operating margin was 28.60%. Those figures form the base for the Ajanta Pharma Q2 results FY27 comparison.\"}},{\"@type\":\"Question\",\"name\":\"What are the main Ajanta Pharma Q2 results expectations this quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No verified analyst estimate is publicly available. The Ajanta Pharma Q2 results expectations centre on revenue against the Rs 1,413.07 crore base, net profit against a profit of Rs 260.19 crore, operating margin against 30.41% in Q1 FY27, and any exceptional item disclosed with the numbers.\"}},{\"@type\":\"Question\",\"name\":\"What is Ajanta Pharma share price today ahead of the Q2 earnings?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Ajanta Pharma share price is Rs 3,552.70 on the NSE as of 9 September 2026, down 0.74% from Rs 3,579.30. The stock is about 6.4% below its 52-week high of Rs 3,796.00 and 52.5% above its 52-week low of Rs 2,329.90, at a market capitalisation of Rs 44,778 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is Ajanta Pharma a good stock to buy before the Q2 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This article does not offer a buy, sell or hold recommendation on Ajanta Pharma Ltd.. The stock trades at a price-to-book ratio of 9.89 with a return on equity of 23.33%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ajanta Pharma Q2 results FY27 date is not yet confirmed by the exchanges. Here is the September 2026 quarter watchlist for Ajanta Pharma Ltd., built on actual Q1 FY27 and Q2 FY26 numbers with no invented estimates.<\/p>\n","protected":false},"author":29,"featured_media":236136,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5331],"tags":[],"class_list":["post-236138","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-https-univest-in-blogs-category-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["236136"],"rank_math_title":["Ajanta Pharma Q2 Results FY27: Date and Expectations"],"rank_math_description":["Ajanta Pharma Q2 results FY27 preview: results date status, key expectations, Q1 FY27 and Q2 FY26 actuals plus valuation before the September 2026 print."],"rank_math_focus_keyword":["Ajanta Pharma Q2 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/ajanta-pharma-q2-results-fy27-preview-date-expectations.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/236138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=236138"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/236138\/revisions"}],"predecessor-version":[{"id":236139,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/236138\/revisions\/236139"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/236136"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=236138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=236138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=236138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}